You are here
NEUROP, INC.
UEI: ZTVMGH5HG328
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Preclinical assessment of the GluN2B inhibitor clinical candidate NP10679 as a medication to prevent opiate abuse relapse
Amount: $301,303.00Abstract The current status of opiate abuse in the US has been characterized as arapidly evolving publichealth crisisrequiring the need for new treatments to address the problemPersistent relapse toad ...
STTRPhase I2018Department of Health and Human Services National Institutes of Health -
Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective,Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage
Amount: $3,616,591.00Abstract Subarachnoid hemorrhageSAHremains a serious source of neurological morbiditywith approximatelycases reported in the US each yearDespite advances in treating the initial and subsequent bleedsp ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics
Amount: $219,338.00DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate ...
STTRPhase I2014Department of Health and Human Services National Institutes of Health -
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme
Amount: $2,675,001.00DESCRIPTION (provided by applicant): Cerebral ischemia is a major cause of death and long-term disability, with high accompanying social and medical costs. Approximately 795,000 Americans suffer a str ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
Optimization of Novel NR2C and NR2D subunit-selective NMDA receptor potentiators
Amount: $691,992.00DESCRIPTION (provided by applicant): Schizophrenia is a chronic neurological disorder that affects approximately 1% of the world population and causes gt 60 billion dollars of direct and indirect soc ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme
Amount: $3,159,861.00DESCRIPTION provided by applicant Cerebral ischemia is a major cause of death and long term disability with high accompanying social and medical costs Approximately Americans suffer a str ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme
Amount: $299,541.00DESCRIPTION (provided by applicant): Cerebral ischemia is a major cause of death and long-term disability, with high accompanying social and medical costs. Approximately 795,000 Americans suffer a str ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Evaluation of pH Dependent Neuroprotectants in SAH Model
Amount: $144,137.00DESCRIPTION (provided by applicant): The goal of this STTR project is to determine if NeurOp's pH-sensitive NMDAR antagonists improve functional recovery and reduce neuronal injury in a validated muri ...
STTRPhase I2008Department of Health and Human Services National Institutes of Health -
Neuroprotection of pH Sensitive NMDAR Antagonists in Cardiopulmonary Bypass Surge
Amount: $125,788.00DESCRIPTION (provided by applicant): Heart operations involving the use of cardiopulmonary bypass (CPB) are among the most common surgical procedures in the world, with over 500,000 performed in the U ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
pH-Sensitive Glutamate Receptor Inhibitors: Clinical Candidate Selection
Amount: $1,403,580.00DESCRIPTION (provided by applicant): Ischemic injury of the brain is a major cause of death and morbidity, and often causes long term disability. NMDA receptor (NMDAR) blockers, particularly targeting ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health